Management of prolonged cytopenia following CAR T-cell therapy

Competing interests

RS- consultancy to Medxus and MyBiotics. MAP- honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Caribou Biosciences, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. He serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT) and on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Executive Committee, and previously served on the Board of Directors of Be The Match (National Marrow Donor Program, NMDP). GS- research funding to the institution from Janssen, Amgen and Beyond Spring.

Source

Similar Posts